GlassScriptPhysician profile
Anh Nguyen
NPI 1265759823
$1,852.73
in general payments reported to CMS, 2019-2025
16 companies · $215 in 2025
The $215 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2021: $120 · 2023: $468 · 2024: $929 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,612.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $544.85 | 2024-2025 | Qelbree |
| Fujifilm Healthcare Americas Corporation | $261.84 | 2023-2024 | Fujifilm |
| Boston Scientific Corporation | $194.63 | 2021-2023 | Resolution 360 Clip |
| Medtronic, INC. | $172.89 | 2023 | Endoflip |
| Corcept Therapeutics | $128.25 | 2025 | Korlym |
| Erbe USA INC | $120.00 | 2019 | |
| Genzyme Corporation | $103.08 | 2024 | |
| Abbvie INC. | $92.34 | 2023 | |
| Phathom Pharmaceuticals, INC. | $79.22 | 2024 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $73.12 | 2024-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $28.78 | 2024 | Rebyota |
| Takeda Pharmaceuticals U.S.A., INC. | $26.58 | 2021 | |
| Braintree Laboratories, INC. | $13.78 | 2021 | |
| Teleflex LLC | $13.37 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anh Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.